Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults.

Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, Villes V, Chêne G, Raffi F; ANRS CO8 APROCO-COPILOTE study group.

AIDS. 2009 May 15;23(8):1021-4. doi: 10.1097/QAD.0b013e3283292195.

2.

Characteristics and survival of HIV-infected patients not screened for hepatitis C virus infection in a hospital-based cohort.

Bénet T, D'Oliveira A Jr, Voirin N, Livrozet JM, Cotte L, Peyramond D, Chidiac C, Touraine JL, Fabry J, Trepo C, Allard R, Vanhems P.

J Viral Hepat. 2007 Oct;14(10):730-5.

PMID:
17875008
3.

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.

Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T; MultivirC Group.

Hepatology. 2001 Aug;34(2):283-7.

PMID:
11481613
4.

Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study.

Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, Strady C, Chêne G, Leport C, Moing VL; ANRS CO8 (APROCO-COPILOTE) Study Group.

J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):407-15. doi: 10.1097/QAI.0b013e3181acb65f.

PMID:
19474755
5.

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T.

Hepatology. 1999 Oct;30(4):1054-8.

PMID:
10498659
6.

Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

Macías J, Pineda JA, Lozano F, Corzo JE, Ramos A, León E, García-García JA, Fernández-Rivera J, Mira JA, Gómez-Mateos J.

Eur J Clin Microbiol Infect Dis. 2003 Nov;22(11):675-80. Epub 2003 Oct 23.

PMID:
14574616
7.

Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.

Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB, Nielsen H, Moller A, Sorensen HT, Obel N.

Clin Infect Dis. 2006 May 15;42(10):1481-7. Epub 2006 Apr 12.

PMID:
16619163
8.

Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001.

Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB.

Arch Intern Med. 2004 Nov 22;164(21):2349-54.

PMID:
15557414
9.

Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.

Neau D, Winnock M, Castéra L, Bail BL, Loko MA, Géraut L, Dupon M, Ragnaud JM, Lacoste D, Lafon ME, Bioulac-Sage P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):168-73.

PMID:
17527092
10.

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.

Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, Vernazza P, Bernasconi E, Mueller NJ, Weber R.

Clin Infect Dis. 2010 Feb 15;50(4):502-11. doi: 10.1086/649922.

PMID:
20085465
11.

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592.

PMID:
19590432
12.

High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.

Laurent C, Bourgeois A, Mpoudi-Ngolé E, Kouanfack C, Ciaffi L, Nkoué N, Mougnutou R, Calmy A, Koulla-Shiro S, Ducos J, Delaporte E.

HIV Med. 2010 Jan;11(1):85-9. doi: 10.1111/j.1468-1293.2009.00742.x. Epub 2009 Jul 29.

13.

Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients.

Shores NJ, Maida I, Soriano V, Núnez M.

J Hepatol. 2008 Sep;49(3):323-8. doi: 10.1016/j.jhep.2008.04.010. Epub 2008 May 5.

PMID:
18486266
14.

Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.

Protopopescu C, Raffi F, Brunet-François C, Salmon D, Verdon R, Reboud P, Carrieri MP, Leport C, Spire B, Michel L; APROCO-COPILOTE (ANRS CO8) Study Group.

Antivir Ther. 2012;17(6):1079-83. doi: 10.3851/IMP2102. Epub 2012 Apr 27.

PMID:
22544079
15.

Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France.

Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, Delamare C, Cyran C, Van Hoenacker AF, Frémaux D, Josse P, Emmanuelli J, Le Strat Y, Desenclos JC, Filoche B.

Epidemiol Infect. 2004 Aug;132(4):699-708.

16.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J; EuroSIDA Study Group.

J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.

PMID:
16107951
17.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251
18.

Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.

Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO, Chang SW.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-9.

PMID:
16044016
19.

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.

Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5. doi: 10.1097/QAI.0b013e31815d2f59.

PMID:
18223361
20.

Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician.

Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, Spire B, Dabis F, Carrieri MP; ANRS-CO13-HEPAVIH study group.

Drug Alcohol Depend. 2011 Jul 1;116(1-3):228-32. doi: 10.1016/j.drugalcdep.2010.09.025. Epub 2011 Jan 15.

PMID:
21239121

Supplemental Content

Support Center